HomeCompareBMY vs UN

BMY vs UN: Dividend Comparison 2026

BMY yields 4.17% · UN yields 4.00%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 BMY wins by $92.5K in total portfolio value
10 years
BMY
BMY
● Live price
4.17%
Share price
$59.73
Annual div
$2.49
5Y div CAGR
37%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$120.5K
Annual income
$39,823.66
Full BMY calculator →
UN
UN
● Live price
4.00%
Share price
$50.00
Annual div
$2.00
5Y div CAGR
5%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$28.0K
Annual income
$899.19
Full UN calculator →

Portfolio growth — BMY vs UN

📍 BMY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBMYUN
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BMY + UN cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BMY pays
UN pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BMY
Annual income on $10K today (after 15% tax)
$354.34/yr
After 10yr DRIP, annual income (after tax)
$33,850.11/yr
UN
Annual income on $10K today (after 15% tax)
$340.00/yr
After 10yr DRIP, annual income (after tax)
$764.31/yr
At 15% tax rate, BMY beats the other by $33,085.80/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BMY + UN for your $10,000?

BMY: 50%UN: 50%
100% UN50/50100% BMY
Portfolio after 10yr
$74.3K
Annual income
$20,361.43/yr
Blended yield
27.41%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on BMY right now

BMY
Analyst Ratings
19
Buy
20
Hold
2
Sell
Consensus: Hold
Price Target
$62.73
+5.0% upside vs current
Range: $40.00 — $75.00
Altman Z
2.3
Piotroski
8/9
UN
Analyst Ratings
7
Buy
15
Hold
7
Sell
Consensus: Hold
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BMY buys
0
UN buys
2
PoliticianChamberTickerTypeAmountDate
Peter Welch🏢 House$UN▼ Sell$15,001 - $50,0002021-11-18
David Perdue🏛 Senate$UN▼ Sell$1,001 - $15,0002020-04-14
David Perdue🏛 Senate$UN▼ Sell$1,001 - $15,0002020-04-14
David Perdue🏛 Senate$UN▲ Buy$1,001 - $15,0002019-02-25
Patty Murray🏛 Senate$UN▼ Sell$1,001 - $15,0002017-06-15
David Perdue🏛 Senate$UN▼ Sell$1,001 - $15,0002017-05-24
Patty Murray🏛 Senate$UN▲ Buy$1,001 - $15,0002017-03-16
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBMYUN
Forward yield4.17%4.00%
Annual dividend / share$2.49$2.00
Payout ratio50%50%
1-year div growth0%5%
5-year div CAGR37%5%
Portfolio after 10y$120.5K$28.0K
Annual income after 10y$39,823.66$899.19
Total dividends collected$91.0K$6.4K
Payment frequencyquarterlyquarterly
SectorHealthcareStock
Analyst consensusHoldHold

Year-by-year: BMY vs UN ($10,000, DRIP)

YearBMY PortfolioBMY Income/yrUN PortfolioUN Income/yrGap
1← crossover$11,271$571.12$11,120$420.00+$151.00BMY
2$12,884$824.20$12,357$458.31+$527.00BMY
3$14,993$1,206.32$13,721$499.76+$1.3KBMY
4$17,839$1,797.27$15,227$544.58+$2.6KBMY
5$21,826$2,738.11$16,885$593.02+$4.9KBMY
6$27,643$4,289.31$18,713$645.34+$8.9KBMY
7$36,534$6,955.64$20,724$701.81+$15.8KBMY
8$50,861$11,770.13$22,938$762.73+$27.9KBMY
9$75,402$20,980.23$25,372$828.41+$50.0KBMY
10$120,504$39,823.66$28,047$899.19+$92.5KBMY

BMY vs UN: Complete Analysis 2026

BMYHealthcare

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis. It also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a protein-bound chemotherapy product; Reblozyl for the treatment of anemia in adult patients with beta thalassemia; and Empliciti for the treatment of multiple myeloma. In addition, the company offers Zeposia to treat relapsing forms of multiple sclerosis; Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma; Inrebic, an oral kinase inhibitor indicated for the treatment of adult patients with myelofibrosis; and Onureg for the treatment of adult patients with AML. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in New York, New York.

Full BMY Calculator →

UNStock

UN is a dividend-paying stock. Use this calculator to estimate your future dividend income, DRIP compounding returns, and passive income potential from investing in UN shares.

Full UN Calculator →
📬

Get this BMY vs UN comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BMY vs SCHDBMY vs JEPIBMY vs OBMY vs KOBMY vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.